Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Bullinger

Showing results (331-340 of 385) with videos related to

Pageof 39
Sort By:
European Journal of Heart Failure|August 6, 2025
Clinical and echocardiographic phenotype of cardiac wasting in patients with advanced cancerMarkus S Anker, Muhammad Shahzeb Khan, Anja Nikolski, et al.
Trials|October 7, 2020
A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trialMaike Janssen, Ulrike Schäkel, Carine Djuka Fokou, et al.
Leukemia|May 26, 2022
The bone marrow niche regulates redox and energy balance in MLL::AF9 leukemia stem cellsAna C Viñado, Isabel A Calvo, Itziar Cenzano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2023
Genetic Characterization of Primary Mediastinal B-Cell Lymphoma: Pathogenesis and Patient OutcomesDaniel Noerenberg, Franziska Briest, Cornelius Hennch, et al.
Blood Advances|September 30, 2024
Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurinFrank G Rücker, Lars Bullinger, Sibylle Cocciardi, et al.
Blood Advances|April 29, 2022
Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplicationsHartmut Döhner, Daniela Weber, Julia Krzykalla, et al.
Blood|May 2, 2013
Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG)Verena I Gaidzik, Richard F Schlenk, Peter Paschka, et al.
Nature|November 17, 2017
BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylationSimon Raffel, Mattia Falcone, Niclas Kneisel, et al.
Blood|March 22, 2014
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trialStephan Stilgenbauer, Andrea Schnaiter, Peter Paschka, et al.
Blood|September 8, 2018
Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AMLFelicitas Thol, Razif Gabdoulline, Alessandro Liebich, et al.
Pageof 39

Showing results (331-340 of 385) with videos related to

Sort By:
Pageof 39
European Journal of Heart Failure|August 6, 2025
Clinical and echocardiographic phenotype of cardiac wasting in patients with advanced cancerMarkus S Anker, Muhammad Shahzeb Khan, Anja Nikolski, et al.
Trials|October 7, 2020
A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trialMaike Janssen, Ulrike Schäkel, Carine Djuka Fokou, et al.
Leukemia|May 26, 2022
The bone marrow niche regulates redox and energy balance in MLL::AF9 leukemia stem cellsAna C Viñado, Isabel A Calvo, Itziar Cenzano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2023
Genetic Characterization of Primary Mediastinal B-Cell Lymphoma: Pathogenesis and Patient OutcomesDaniel Noerenberg, Franziska Briest, Cornelius Hennch, et al.
Blood Advances|September 30, 2024
Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurinFrank G Rücker, Lars Bullinger, Sibylle Cocciardi, et al.
Blood Advances|April 29, 2022
Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplicationsHartmut Döhner, Daniela Weber, Julia Krzykalla, et al.
Blood|May 2, 2013
Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG)Verena I Gaidzik, Richard F Schlenk, Peter Paschka, et al.
Nature|November 17, 2017
BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylationSimon Raffel, Mattia Falcone, Niclas Kneisel, et al.
Blood|March 22, 2014
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trialStephan Stilgenbauer, Andrea Schnaiter, Peter Paschka, et al.
Blood|September 8, 2018
Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AMLFelicitas Thol, Razif Gabdoulline, Alessandro Liebich, et al.
Pageof 39